AP3 Rec'd PCT/PTO 04 MAY 2008


PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

.;

	ANSMITTAL LETTER TO	ATTORNEY'S DOCKET NUMBER 8024-012-US					
DESIGNATED/ELECTED OFFICE (DO/EO/US)			U.S. APPLICATIONINO. (If known, see \$7 GFR 15)				
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371			70/2/0002				
	TIONAL APPLICATION NO. JS2004 1036551	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED				
	INVENTION						
SIN	TMESIS OF GIVE OPE	ptides with Superio	r Pharmacolinetic Properties				
Oot	ing for dozeolos	cals Inc					
Applicant			O/US) the following items and other information:				
1. 🔽	1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.						
2. 🔲 🛚	This is a SECOND or SUBSEQUENT s	submission of items concerning a submission	n under 35 U.S.C. 371.				
3.	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4.	The US has been elected (Article 31).						
5.	A copy of the International Applicatio	n as filed (35 U.S.C. 371(c)(2))					
	a. is attached hereto (required	only if not communicated by the Internation	nal Bureau).				
	b. has been communicated by	the International Bureau.					
	c. is not required, as the appli	cation was filed in the United States Receiving	ing Office (RO/US).				
6.	An English language translation of th	e International Application as filed (35 U.S.C	C. 371(c)(2)).				
	a. is attached hereto.		·				
<u> </u>	b. has been previously submi	tted under 35 U.S.C. 154(d)(4).					
7.	Amendments to the claims of the Inte	ernational Application under PCT Article 19 ((35 U.S.C. 371(c)(3))				
	a. are attached hereto (requi	red only if not communicated by the Internal	tional Bureau).				
	b. have been communicated	by the International Bureau.					
	c. have not been made; how	ever, the time limit for making such amendn	nents has NOT expired.				
	d. Mave not been made and will not be made.						
8. 📙	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).						
9. 🔽	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
10.	An English language translation of th Article 36 (35 U.S.C. 371(c)(5)).	e annexes of the International Preliminary E	xamination Report under PCT				
Items	11 to 20 below concern document(s	e) or information included:					
11.	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.					
12. 🔽	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
13.	A preliminary amendment.						
14.	An Application Data Sheet under 37 CFR 1.76.						
15.	A substitute specification.						
16. 🔽	A power of attorney and/or change of address letter.						
17.	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.						
18.	A second copy of the published International Application under 35 U.S.C. 154(d)(4).						
19.	A second copy of the English language	ge translation of the international application	under 35 U.S.C. 154(d)(4).				

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER		
4	DIET	2010	PCT/USacoy)	036551	8024-012-	-US
4	ems or information	5 5 5 5				
The follow	ing fees have b	een submitted		····	CALCULATIONS	PTO USE ONLY
,	_			\$300	\$	1
22. Examin	ation fee (37 CF	FR 1.492(c))	· · · · · · · · · · · · · · · · · · ·		300	
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0 All other situations					\$ 200	
23. Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority					\$ 100	
	OTAL OF 21, 22					
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.						
Total Sheets E	Extra Sheets		additional 50 or fraction up to a whole number)	RATE		•
- 100 =	/50 =	/50 = x \$250		\$ 🔿		
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).					\$ 130	
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$	
Total claims		- 20 =		x \$ 50	\$ 500	
Independent claims	i	-3=		× \$200	\$ 0	
MULTIPLE DEPEN	DENT CLAIM(S	i) (if applicable)		+ \$360	\$ 0	
				CALCULATIONS =	\$ 1230	
Applicant claim	s small entity st	atus. See 37 CF	R 1.27. Fees above are reduc	ed by 1/2.	615	
				SUBTOTAL =	\$ 615	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$ 0	
			TOTAL	NATIONAL FEE =	\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 40		
TOTAL FEES ENCLOSED =					\$ 150	
			•		Amount to be refunded:	\$
					Amount to be charged	\$

10/5/8603

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. A check in the amount of \$ to cover the above fees is enclosed.	v sanc				
a. A check in the amount of \$ to cover the above fees is enclosed.	1 Appo				
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 5023.35 A duplicate copy of this sheet is enclosed.					
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should n be included on this form. Provide credit card information and authorization on PTO-2038.	it				
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
SEND ALL CORRESPONDENCE TO: SIGNATURE MICHAEL B. Farber, Esq. NAME 32612 REGISTRATION NUMBER	_				

19/5/8603

PATENT 8024-012-US 1AP20 Rec'd FGVFTO 0 4 MAY 2006

Certificate of Express Mailing

Under 37 CFR 1.10, I certify that the attached correspondence is being deposited with the United States Postal Service as Express Mail No. EV 669528703 US in an envelope addressed to: Mail Stop: PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Date: May 4, 2006

Christina Dueñas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Examiner: TBA
Jonathan Duffield, et al.)	Group Art Unit: TBA
Serial No.: U.S. National Stage of PCT/US2004/036551)))	Docket No.: 8024-012-US
Filed: Herewith)	Date Mailed: May 4, 2006
For: Synthesis of Glycopeptides with Superior Pharmacokinetic Properties)))	

TRANSMITTAL LETTER

Mail Stop: PCT Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This submission is to effect entry of PCT Application PCT/US2004/036551 into the United States National Stage under 35 U.S.C. § 371 and 37 C.F.R. § 1.495.

Accordingly, the following documents are transmitted:

- 1. Transmittal Letter for Submission under 35 USC 371 with Fee Sheet indicating a fee payment of \$150.00, reflecting the basic national stage fee of \$150.00 for a small entity under 37 C.F.R. § 1.492(a) (3 pages);
- 2. An Application Data Sheet under 37 C.F.R. § 1.76 giving biographical information on the inventors of the above-identified application as well as details of the claim for priority based on a previously-filed provisional application (2 pages); and
- 3. A copy of the above-identified PCT application as published under the PCT. Because the above-identified PCT application was filed in the United States Patent and Trademark Office, the copy is not required under 37 C.F.R. § 1.495(b)(i). The copy is provided for convenience. (27 pages).
- A copy of the Response to Invitation to Furnish Nucleotide Sequence Listing.
 (2 pages).
- 5. A copy of the Preliminary Amendment under 37 C.F.R. §§ 1.121 and 1.825. (4 pages).
- 6. A copy of the Declaration of Inventorship under 37 C.F.R. § 1.41(a)(4) originally filed with PCT Application No. PCT/US2004/036551. (2 pages).
- 7. A copy of the Assignment with Recordation Cover Sheet as required under 37 C.F.R. §§ 3.28 and 3.31. This assignment was originally filed with PCT Application No. PCT/US2004/036551. (7 pages).

10/578603 8024-012-US 1AP20Rec'd CTATO 04 MAY 2006

8. A copy of the Power of Attorney and Statement under 37 C.F.R. § 3.73(b). (2 pages).

Priority under 35 U.S.C. §§ 119 and 365 is hereby claimed for the national stage application. This priority is claimed to: (1) PCT Application No. PCT/US2004/036551, filed on November 1, 2004, and designating the United States; (2) United States Provisional Patent Application Serial No. 60/516,838 filed on November 4, 2003; (3) United States Provisional Patent Application Serial No.60/557,631, filed on March 30, 2004; and (4) United States Provisional Patent Application Serial No. 60/598,215 filed on August 2, 2004, from which PCT Application No. PCT/US2004/036551 claimed priority.

Date:

Respectfully submitted,

Michael B. Farber, Ph.D., Esq.

Reg. No.: 32,612

CATALYST LAW GROUP, APC 9710 Scranton Road, Suite 170 San Diego, California 92121 (858) 450-0099 (858) 450-9834 (Fax)